

# Pre-donation Prescription Narcotic Use: A Novel Risk Factor for Readmission after Living Donor Nephrectomy

American Transplant Congress

June 14, 2016

**KL Lentine, MD, PhD,<sup>1</sup> NN Lam, MD, MSc,<sup>2</sup> MA Schnitzler,  
PhD,<sup>1</sup> GP Hess, MD, MSc,<sup>3</sup> BL Kasiske, MD,<sup>4</sup> D Axelrod,  
MD,<sup>5</sup> AX Garg, MD, PhD,<sup>6</sup> J Schold, PhD,<sup>7</sup> H Randall, MD,<sup>1</sup>  
DC Brennan, MD,<sup>8</sup> DL Segev, MD, PhD<sup>9</sup>**



1 Saint Louis University, 2 University of Alberta,  
3 Symphony Health, 4 Hennepin County Medical Center,  
5 Dartmouth University, 6 London Health Sciences Centre,  
7 Cleveland Clinic, 8 Washington University,  
9 Johns Hopkins University

# Disclosures

**Krista L. Lentine, MD, PhD**  
**Professor of Medicine**  
**Saint Louis University, St. Louis, MO, USA**

I have no financial relationships to disclose within the past 12 months relevant to my presentation. The ACCME defines 'relevant' financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

## **AND**

My presentation does/does not include discussion of off-label or investigational use (if yes, list company and nature of relationship – e.g. grants, advisory board, etc.).

I do/do not intend to reference unlabeled/unapproved uses of drugs or products in my presentation (if yes, identify product and unlabeled use).

This work was supported in part by **HRSA contract HSH-250-2015-00009C**. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of HHS, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

This work was also supported by **NIH/NIDDK R01-DK096008**

# Background

- Evidence for counseling living kidney donor (LKD) candidates on perioperative risks – focused on **mortality**
  - Other complications are not well described
- **Readmission** – commonly used measure of **care quality** and **healthcare utilization**
  - Proxy for morbidity and reduced quality of life
- OPTN registry data for U.S. **LKD**, 2005-2012:  
**2.1% readmitted** within 6 weeks
  - **Center reporting** to the OPTN **underestimates** early surgical complications


# Background

State Inpatient Database (SID) [Schold et al, *CJASN* 2014]

- 4 state inpatient databases

- Novel approaches to characterizing perioperative outcomes, including readmission, among confirmed living donor samples are needed

those with preoperation depression (aHR 1.88) or hypothyroidism (aHR 1.63)



- Limitations: Lack of confirmed LKD status through patient level-linkages to the national donor registry

# Database Integration

## Research Strategy

- Linkage of the **national transplant registry** with other data sources – combine value of:

**Confirmed patient status (e.g., LKD, recipient)**

+

**Baseline patient and procedure characteristics**

+

Additional **outcome** and **exposure** information

- **Pharmacy fill records**

- Non-obtrusive measure of **prescribed healthcare**
- Surrogate **measure of comorbidity** in epidemiologic investigations, including among LKD and transplant recipients

# Database Integration

In context of rising use of prescription narcotics nationally, we asked:

- Do prescription narcotic fills before living kidney donation predict readmission as a complication after donor nephrectomy?



# Methods: Design & Study Measures

## ● Data Sources

- Scientific Registry of Transplant Recipients (**SRTR**)
- Symphony Health Solutions (**SHS**) pharmacy claims warehouse
- University HealthSystem Consortium (**UHC**)
  - Alliance of 107 academic medical centers & 234 affiliated hospitals – **90% of US non-profit academic centers**
  - **Sept 2008** to **December 2012**

## ● Sample Identification

- **Patient-Level Linkage, SHS to SRTR** – encrypted tokens (transform name, DOB, sex, ZIP code)
- **Patient-Level Linkage, UHC to SRTR** – transplant center, donation date, donor age, sex

# Methods: Study Measures

| Covariates             | Source   |
|------------------------|--|
| Demographics           | <ul style="list-style-type: none"><li>● <b>SRTR:</b> Age, sex, race, donor-recipient relationship, health insurance (yes/no)</li></ul>   |
| Clinical factors       | <ul style="list-style-type: none"><li>● <b>SRTR:</b> BMI, physical limitations, HTN, smoking</li><li>● <b>UHC: “Present on Admission” dx</b> – obesity, hypertension, &amp; smoking; additional conditions by organ system</li></ul> |
| Procedure              | <ul style="list-style-type: none"><li>● <b>SRTR:</b> Intended procedure type (laparoscopic or open) and side of nephrectomy (left or right)</li><li>● <b>UHC:</b> robotic nephrectomy</li></ul>                                      |
| Payer & Center factors | <ul style="list-style-type: none"><li>● <b>UHC:</b> Payer for donation</li><li>● <b>SRTR:</b> Annual donor nephrectomy volume</li></ul>  |



# Methods: Study Measures

| Outcomes                         | Source   |
|----------------------------------|--|
| <b>Pre-donation Narcotic Use</b> | <ul style="list-style-type: none"><li>● <b>SHS:</b> Pharmacy fills for <b>narcotic medications</b> in the year prior to donation</li><li>● Aggregated and normalized <b>to morphine equivalents (ME)</b></li></ul> |
| <b>Readmission</b>               | <ul style="list-style-type: none"><li>● <b>UHC:</b> Readmissions within 1 year<ul style="list-style-type: none"><li>● <b>Primary diagnosis</b> for the readmission</li></ul></li></ul>                             |

- **11.3% filled  $\geq 1$  narcotic prescription in the year before donation**
- **Narcotic use in year before donation ranked as tertiles:**  
1) **<63 mg, 2) 63 to <157.5 mg, 3) > 157.5 mg**

## **Donor Socio-demographic Information**

### SRTR Live Donor Registry

- Age, Sex, Race
- Donor/recipient relationship
- Donor insurance
- Physical capacity
- Education, Employment status

## **Prescription Narcotic Use**

### SHS Database

- Agent
- Dose (for ME)

## **Pre-Donation Clinical Information**

### SRTR Live Donor Registry

- Height, Weight (for BMI)
- HTN, Blood pressure
- Smoking
- Serum creatinine (for eGFR)

### UHC 'Present on Admission' Diagnoses

- HTN, Obesity, Genitourinary, Cardiac, Respiratory, Gastrointestinal, Hematologic, Neurologic, Endocrine, Rheumatologic, Psychiatric, Smoking

## **Procedure and Center Information**

### SRTR Live Donor Registry

- Procedure: Laparoscopic, Open
- Side of nephrectomy
- Annual volume

### UHC Intended Procedure

- Robotic

### UHC Payer Information (Donation)

- Private, Medicare, Other

**Sample: 14,959 = 55.6% of all U.S. live kidney donations in period**

## **Hospital Readmissions**

### UHC Hospitalization Records

- Diagnoses and Procedures

# Baseline Characteristics


| *p<0.05–0.002; †p=0.001–0.0002; ‡p<0.0001 | No Narcotics<br>(N=13,266) | Level 1<br>(N=516) | Level 2<br>(N=611) | Level 3<br>(N=566) |
|---|----------------------------|--------------------|--------------------|--------------------|
|   | Mean (SD)                  | Mean (SD)          | Mean (SD)          | Mean (SD)          |
| <b>Age (yrs)</b>                          | 42.1 (11.8)                | 42.1 (11.8)        | 41.9 (11.6)        | 42.9 (11.3)        |
|   | (%)                        | (%)                | (%)                | (%)                |
| <b>Female</b>                             | 60.9                       | <b>70.5‡</b>       | <b>68.7†</b>       | <b>65.4*</b>       |
| <b>Race</b>                               |                            | *                  | *                  | ‡                  |
| White                                     | 72.0                       | <b>75.4</b>        | <b>74.6</b>        | <b>81.5</b>        |
| African American                          | 11.5                       | 13.8               | 13.6               | 11.7               |
| Hispanic                                  | 11.3                       | 8.5                | 8.5                | 4.8                |
| Other                                     | 5.2                        | 2.3                | 3.3                | 2.1                |
| <b>Obese (BMI ≥30)</b>                    | 20.7                       | 21.1               | 24.6               | <b>26.7†</b>       |
| <b>Comorbidity</b>                        |                            |                    |                    |                    |
| Hypertension                              | 12.1                       | 11.6               | 12.6               | 13.3               |
| Genitourinary                             | 1.9                        | 2.5                | 2.0                | 2.8                |
| Cardiac                                   | 0.9                        | 0.2                | 1.2                | 1.6                |
| Respiratory                               | 5.2                        | 7.0                | <b>7.9*</b>        | <b>8.0*</b>        |

## Baseline Characteristics, cont.


|                             | No Narcotics | Level 1      | Level 2      | Level 3      |
|-----------------------------|--------------|--------------|--------------|--------------|
|                             | (%)          | (%)          | (%)          | (%)          |
| Gastrointestinal            | 7.9          | 8.7          | 9.7          | <b>10.8*</b> |
| Hematologic                 | 1.6          | 1.7          | <b>2.6*</b>  | 1.6          |
| Neurologic                  | 0.3          | 0.0          | 0.5          | 0.7          |
| Endocrine                   | 11.6         | 13.0         | 13.3         | <b>14.8*</b> |
| Rheumatologic               | 0.2          | 0.0          | 0.3          | 0.4          |
| Psychiatric                 | 7.0          | 8.9          | <b>10.2*</b> | <b>11.0†</b> |
| Smoking                     | 8.5          | <b>11.6*</b> | 9.3          | <b>14.3‡</b> |
| <b>Nephrectomy type</b>     |              |              |              |              |
| Laparoscopic                | 94.0         | 4.3          | 3.9          | 4.6          |
| Robotic                     | 2.4          | 92.4         | 93.6         | 92.4         |
| Left                        | 86.5         | 3.3          | 2.5          | 3.0          |
| <b>Annual center Volume</b> |              |              |              |              |
| ≤10                         | 1.9          | 1.2          | 1.3          | 1.8          |
| 11-50                       | 41.1         | 40.3         | 44.2         | 44.5         |
| >50                         | 57.0         | 58.5         | 54.5         | 53.7         |

# Results

- Overall 1 year readmission rate – 3.6%
- Pre-donation narcotic use level bore graded associations with 1-year readmission
  - LKD with the highest pre-donation narcotic use were twice as likely to be readmitted as non-users (6.6% vs 3.2%, aOR 1.94)



# Readmission, by Other Factors




# Readmission Diagnoses, by Narcotic Use Level

**Most common primary medical diagnoses for readmission after donor nephrectomy, according to pre-donation narcotic use level**

| No Narcotics                       |       | Level 1 Use                                      |       | Level 2 Use                                |       | Level 3 use                           |       |
|------------------------------------|-------|--|-------|--|-------|---------------------------------------|-------|
| Diagnosis                          | %     | Diagnosis  | %     | Diagnosis                                  | %     | Diagnosis                             | %     |
| Hernia                             | 10.0% | Hernia   | 19.1% | Infection                                  | 14.7% | Infection                             | 26.2% |
| Digestive system complications NEC | 7.0%  | Infection  | 14.3% | Digestive system complications NEC         | 8.8%  | Digestive system complications NEC    | 15.8% |
| Infection                          | 8.4%  | Abdominal pain                                   | 9.5%  | Abdominal pain                             | 8.8%  | Incisional hernia without obstruction | 7.9%  |
| Constipation                       | 5.4%  | Nausea with vomiting; other digestive complaints | 9.5%  | Nausea and/ or vomiting                    | 8.8%  | Dehydration                           | 5.3%  |
| Dehydration                        | 3.3%  | Sprains and strains                              | 9.5%  | Paralytic ileus or intestinal obstruction  | 5.9%  | Paralytic ileus                       | 5.3%  |
| Nausea with vomiting               | 3.0%  | Paralytic ileus                                  | 4.8%  | Unspecified gastritis and gastroduodenitis | 2.9%  | Other disorders of the peritoneum     | 5.3%  |

- Most common readmission diagnoses: **hernias, gastrointestinal complications (GI), and infections**
- **GI complications & infection** appear to predominate in those with the highest predonation narcotic use





# Limitations

## Design & Data

- Results **may not generalize** to LKD donating at nonacademic centers, or outside the U.S.
- **Retrospective, observational** design identifies associations but cannot prove causation
- **Unable** to account for **illicit drug use, “pharmacy shopping”** behaviors, or narcotic prescription fills outside of insurance benefits
- Unable to capture readmissions **outside the recovery hospital**

# Strengths

## Design & Data

- **Verification of donor status** through linkage with the national donor registry
- Capture of **readmission events** independent of center reporting
- **Pharmacy fill records** as a novel **pre-donation exposure**

# Conclusions

- Linkage of the **national transplant registry** with administrative records from a **pharmacy claims database** and an **academic hospital consortium** enabled characterization of **correlates of readmission** after donor nephrectomy
- **Pre-donation narcotic use** is a **novel risk factor** for readmission after donation
  - Associations may in part reflect narcotic use as a measure of comorbidity, but relevant to **risk stratification** and **counseling**
- Future work should investigate **underlying mechanisms** and approaches to **optimizing post-donation outcomes**

